Protalix BioTherapeutics (PLX) Inventory Average (2011 - 2026)

Protalix BioTherapeutics has reported Inventory Average for 15 years, with the latest figure at $28.1 million in Q1 2026.

• For the quarter ending Q1 2026, Inventory Average rose 37.92% year-over-year to $28.1 million; the trailing twelve-month figure through Mar 2026 stood at $28.1 million (up 37.92% YoY), and the FY2025 full-year result was $23.5 million, up 16.59% from the prior year.
• Inventory Average for Q1 2026 stood at $28.1 million, up from $23.5 million in the prior quarter.
• The five-year high for Inventory Average was $28.1 million in Q1 2026, with the low at $15.5 million in Q3 2022.
• Average Inventory Average over 5 years is $19.9 million, with a median of $20.3 million recorded in 2023.
• Year-over-year, Inventory Average slipped 8.01% in 2024 and surged 37.92% in 2026.
• Tracing PLX's Inventory Average over 5 years: stood at $15.7 million in 2022, then increased by 29.53% to $20.3 million in 2023, then fell by 5.38% to $19.2 million in 2024, then advanced by 22.22% to $23.5 million in 2025, then gained by 19.62% to $28.1 million in 2026.
• The last three Inventory Average figures came in at $28.1 million (Q1 2026), $23.5 million (Q4 2025), and $21.2 million (Q3 2025), per Business Quant data.

Peer Comparison